The round was led by Agilent Technologies and includes participation from existing investors Research Corporation Technologies, Broad Oak Capital Partners, BioAdvance, and members of the Board of Directors and senior management.

Halo Labs is an instrumentation and consumable company that commercializes high throughput aggregate, visible and subvisible particle analysis for biopharmaceutical formulation, stability, and product quality control using state-of-the-art custom optics and image processing techniques. Researchers around the globe depend on Halo Labs for unprecedented insights into aggregates and subvisible particles present in their drug products via optical imaging on membranes.